Filing Flows › 8-K events › Seres Therapeutics
Seres Therapeutics: results of operations
Form 8-K filed Nov 4, 2026 · items 2.02, 7.01
FDA decisionsSERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)
What the filing says
SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC) Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments,
Read the filing on SEC EDGAR →
What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →
Seres Therapeutics at a glance
Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year). The chart follows the revenue to costs, profit and cash.
Seres Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →
Seres Therapeutics’s other material 8-Ks
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.